FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
13.0 ptn (24u)Health & MedicineOne-Off3mnd
KalshiBeschikbaarheid controlerenKYC vereist2% kostenGeverifieerde afwikkelingsgegevensRedelijk gekalibreerdHuidige impliciete kans
Ja 98%+13.0pt
Marktkwaliteit
47 / 100
Lage kwaliteit24u volume
€ 480,1
Liquiditeit
€ 1,3K
Lage liquiditeitBied / Laat
91.0% / 99.0%
Spread
8.0 pt
Brede spreadMarktdata
Bijgewerkt 9 minuten geleden
17 jun 26, 21:30 UTC1 jan 27, 04:59 UTC
Trends
Gerelateerde Markten
Gerelateerde vragen voor context, geen vergelijking van gelijkwaardige contracten.
FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
KalshiFDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
KalshiFDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (in 2026)
KalshiEbola pandemic in 2026?
PolymarketHantavirus pandemic in 2026?
PolymarketFDA approves skin cancer vaccine by which date?
PolymarketRegels
If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Afwikkeling via:AppliedXL
- This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued.
- Anitocabtagene autoleucel (anito-cel) is a personalized, one-time cell therapy made from a patient's own immune cells, reprogrammed in a laboratory to hunt and destroy cancer cells — think of it as taking a soldier from the patient's own army, giving it a custom-made targeting scope, and sending it back in.
- It is classified as a CAR-T (chimeric antigen receptor T-cell) therapy developed by Arcellx and commercialized in partnership with Gilead Sciences, designed to treat a blood cancer called multiple myeloma.
- In the trials studied here, it showed very high response rates, with nearly all treated patients responding to the therapy.
Open markten
Health & MedicinePOLYMARKETHantavirus pandemic in 2026?
- No-0.1pt97%
- Yes+0.1pt3%
- Totaal volume
- € 15,6 mln.
- 24u volume
- € 18,3K
KALSHIWill WHO declare Hantavirus a Public Health Emergency of International Concern this Year?
- No96%
- Yes+1.9pt4%
- Totaal volume
- € 1,6 mln.
- 24u volume
- € 5,2K
KALSHIWhen will Intellia Therapeutics submit a BLA for Lonvo-z?
- before October+64.0pt98%
- before 2027+22.0pt98%
- before December+30.0pt98%
+3 extra uitkomsten
POLYMARKETFDA approves skin cancer vaccine by which date?
- December 31,+6.0pt65%
- September+2.0pt41%
- June28%
- Totaal volume
POLYMARKETNew pandemic in 2026?
- No+0.5pt94%
- Yes-0.5pt6%
- Totaal volume
- € 916K
- 24u volume
- € 1,5K
KALSHIMeasles cases in 2026?
- Above 300099%
- Above 400097%
- Above 6000-2.0pt57%
+2 extra uitkomsten
- Totaal volume
- € 863,6K
- 24u volume
- € 1K
- Ebola pandemic in 2026?
- Will 3 mg THC beverages be federally legal to sell?
- Ebola pandemic in 2026?
- Measles cases in U.S. in 2026?
- FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)
- When will Heidi Overton be confirmed as Commissioner of the FDA?
- What will the average number of measles cases be during Trump's term?
- Will the FDA approve any psychedelic substance for medical use this year?
- When will the FDA reclassify BPC-157 to Category 1?
- FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
- Will the FDA approve CagriSema?
Veelgestelde vragen
- Wat zijn de huidige kansen voor FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)?
- Kalshi prijst Yes op 98% per 8 september 2026.
- Wanneer wordt FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) afgewikkeld?
- FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) wordt naar verwachting op 1 januari 2027 afgewikkeld.
- Hoe wordt FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026) afgewikkeld?
- Kalshi wikkelt deze markt als volgt af: If the FDA's decision on Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences in 2026 is a full approval or an accelerated approval, the market resolves to Yes.